| abstract |
COMPOUND OR A SALT, PRODUCT OR SOLVATE OF THE SAME, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING GLK-MEDIATED DISEASES, AND PROCESS FOR PREPARING A COMPOUND wherein R¬ 1¬ is methoxymethyl; R¬ 2¬ is selected from -C (O) NR¬ 4¬R¬ 5¬, -SOÐR¬ 4¬R¬ 5¬, -S (O) <sym> R¬ 4¬ and HET-2; HET-1 is an optionally substituted 5 or 6 membered C-linked heteroaryl ring; HET-2 is an optionally substituted 4-, 5- or 6-membered C- or N-linked heterocyclyl ring; R¬ 3¬ is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R¬4¬ is selected, for example, from hydrogen, optionally substituted (1-4C) alkyl and HET-2; R¬5¬ is hydrogen or (1-4C) alkyl or R¬4¬ and R¬5¬ together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is, for example, an optionally substituted 4-, 5- or 6-membered saturated or partially unsaturated heterocyclyl ring; p is (regardless of each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n will be 1 or 2 or a salt, prodrug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described. |